Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SBC Medical Group Holdings (SBCWW) Interest Expenses (2023 - 2025)

Historic Interest Expenses for SBC Medical Group Holdings (SBCWW) over the last 3 years, with Q3 2025 value amounting to $48635.0.

  • SBC Medical Group Holdings' Interest Expenses fell 9388.36% to $48635.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 9222.2%. This contributed to the annual value of $5.5 million for FY2024, which is 63279.86% up from last year.
  • Per SBC Medical Group Holdings' latest filing, its Interest Expenses stood at $48635.0 for Q3 2025, which was down 9388.36% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, SBC Medical Group Holdings' Interest Expenses registered a high of $2.7 million during Q4 2024, and its lowest value of $48635.0 during Q3 2025.
  • For the 3-year period, SBC Medical Group Holdings' Interest Expenses averaged around $956011.8, with its median value being $795158.0 (2024).
  • Per our database at Business Quant, SBC Medical Group Holdings' Interest Expenses skyrocketed by 155370.28% in 2024 and then tumbled by 9388.36% in 2025.
  • SBC Medical Group Holdings' Interest Expenses (Quarter) stood at $164280.0 in 2023, then skyrocketed by 1553.7% to $2.7 million in 2024, then plummeted by 98.21% to $48635.0 in 2025.
  • Its last three reported values are $48635.0 in Q3 2025, $1.1 million for Q2 2025, and $1.7 million during Q1 2025.